US Edition
Published • loading... • Updated
StockWatch: Wave Plummets 50% on Obesity Data
Disappointed investors punished Wave Life Sciences (NASDAQ: WVE), causing its shares to lose roughly half their value on Thursday after the RNA-based drug developer reported mixed early-stage clinical data for its obesity candidate WVE-007, showing a less than 1% reduction in body weight six months after receiving the high dose. Investors zeroed in on the mere 0.9% dip in body weight and 3.3% decline in waist circumference (both placebo-adjusted…
1 Articles
1 Articles
StockWatch: Wave Plummets 50% on Obesity Data
Disappointed investors punished Wave Life Sciences (NASDAQ: WVE), causing its shares to lose roughly half their value on Thursday after the RNA-based drug developer reported mixed early-stage clinical data for its obesity candidate WVE-007, showing a less than 1% reduction in body weight six months after receiving the high dose. Investors zeroed in on the mere 0.9% dip in body weight and 3.3% decline in waist circumference (both placebo-adjusted…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
